Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors

Journal of Sichuan University (Medical Science)

Volumn 37, Issue 6, 2006, Pages 868-871

  Liu, Jia Gang ^a   Liu, Yan Hui ^a   Cai, Jing ^a   Liu, Xue Song ^a   Song, Wei Zheng ^a   Huang, Yi ^a   Mao, Qing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

EGFR; Malignancy brain tumor; PTEN

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; BRAIN CANCER; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; EPENDYMOMA; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; OLIGODENDROGLIOMA; PROGNOSIS; PROTEIN EXPRESSION;

EID: 33845238492     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Wang LQ, Ignat A, Axiotis CA. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors : progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Applied Immunohistochemistry & Molecular Morphology, 2002;10(2):139-146.
2. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res,2001;61(3):1122-1128.
3. Marquez A, Wu R, Zhao JX, et al. Evaluation of EGFR by chromogenic in situ hybridization and archival gliomas using bright filed microscopy. Diagnositic Molecular Pathology, 2004; 13(1):1-8.
4. Tong CY, Hui AB, Yin XL, et al. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array- based comparative genomic hybridization. Neurosurg,2004;100(2):187-193.
5. Barker FG, Simmons ML, Chang SM, et al. EGFR overexpression and radiation response in glioblastoma multiform. Int J Radiat Oncol Biol Phys,2001; 51 (2) : 410-418.
6. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res, 2000; 12 (2):107-112.
7. Knobbe CB, Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol,2003;13(4):507- 518.
8. Tada K, Shiraishi S, Kamiryo T, et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors : correlation with patient age and survival. J Neurosurg,2001;95(4):651-659.
9. Hoang XK, He J, Huguet S, Mokhtari K, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology,2001;57(7):1278-1281.
10. Ebert C, Haken M, Meyer B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol,1999;155(2):627-632.
11. Ali IU, SchrimL LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst,1999;91(22):1922-1932.